Clinical Trial Update: The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease

View source ↗

Summary

This clinical trial update evaluates whether changes in the serum biomarker KL-6 can help evaluate disease development across different diffuse parenchymal lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Parenchymal Lung Disease

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Diffuse Parenchymal Lung Disease | Status: UNKNOWN